Pneumocystosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:723B48.5+J17.2*
Who is this for?
Show terms as
7Active trials44Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Pneumocystosis, also called Pneumocystis pneumonia (PCP), is a serious lung infection caused by a fungus called Pneumocystis jirovecii (previously known as Pneumocystis carinii). This fungus is found almost everywhere in the environment and does not usually cause illness in healthy people. However, in people whose immune system is weakened — such as those living with HIV/AIDS, people receiving chemotherapy, or organ transplant recipients on immune-suppressing medications — the fungus can multiply in the lungs and cause a dangerous infection. The infection mainly affects the lungs, causing inflammation and making it hard to breathe. The air sacs in the lungs fill with fluid and fungal organisms, which reduces the amount of oxygen the body can absorb. Without treatment, the infection can become life-threatening very quickly. The most common symptoms include a dry cough, shortness of breath (especially with activity), fever, and tiredness. Some people also experience chest tightness or discomfort. Symptoms often come on gradually over days to weeks. The good news is that pneumocystosis can be treated effectively with antibiotics, especially a drug called trimethoprim-sulfamethoxazole (TMP-SMX), also known as co-trimoxazole. People at high risk can also take preventive medication to stop the infection from happening in the first place. Early diagnosis and treatment greatly improve outcomes.

Key symptoms:

Dry, non-productive coughShortness of breath, especially during physical activityFever and chillsFatigue and low energyChest tightness or discomfortRapid breathingLow blood oxygen levelsNight sweatsUnintended weight lossDifficulty completing everyday tasks due to breathlessness

Clinical phenotype terms (23)— hover any for plain English
Acute infectious pneumoniaHP:0011949Pneumocystis jirovecii pneumoniaHP:0020102Respiratory failure requiring assisted ventilationHP:0004887Interstitial pneumonitisHP:0006515Abnormal total neutrophil countHP:0011991Combined cystic and ground-glass pattern on pulmonary HRCTHP:0025395Nonproductive coughHP:0031246Multiple pulmonary cystsHP:0005948Chronic oral candidiasisHP:0009098
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

McGill University Health Centre/Research Institute of the McGill University Health Centre — PHASE4

TrialNOT YET RECRUITING
Jan 2026How Long Should we Give Steroids for Patients With Severe PCP

McGill University Health Centre/Research Institute of the McGill University Health Centre — PHASE4

TrialNOT YET RECRUITING
Nov 2025Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

Todd C. Lee MD MPH FIDSA — PHASE3

TrialRECRUITING
Sep 2025Corticosteroids for PJP in Non-HIV Immunocompromised Adults

Qingyuan Zhan — PHASE3

TrialNOT YET RECRUITING
Sep 2025Pneumocystis Jirovecii Genotyping

Nottingham University Hospitals NHS Trust

TrialNOT YET RECRUITING
Jun 2025CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

University Hospital, Tours — PHASE1, PHASE2

TrialNOT YET RECRUITING
Apr 2025Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

Assistance Publique - Hôpitaux de Paris

TrialNOT YET RECRUITING
Dec 2024Implementation of the Personalized Care Plan (PCP) Proposed at the End of Step 2 of the ICOPE Program

MSPU de Pins-Justaret

TrialRECRUITING
Dec 2024PIECES - Towards Large-Scale Adaptation and Tailored Implementation of Primary Cancer Prevention Programs

Hidde van der Ploeg — NA

TrialENROLLING BY INVITATION
Jul 2024Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

Tongji Hospital — PHASE4

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Pneumocystosis.

7 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

7 recruitingView all trials with filters →
Phase 31 trial
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
Phase 3
Actively Recruiting
PI: Emily G McDonald, MD MSc (Research Institute of the McGill University Health) · Sites: Montreal, Quebec · Age: 18100 yrs
Phase 41 trial
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
Phase 4
Actively Recruiting
PI: Lingli Dong (Tongji Hospital) · Sites: Wuhan, Hubei · Age: 1899 yrs
Phase 21 trial
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
Phase 2
Actively Recruiting
PI: Mohit Joshi, MD (Mundipharma Research Limited) · Sites: Cape Town; Johannesburg +4 more · Age: 1899 yrs
N/A1 trial
Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS
N/A
Enrolling by Invitation
PI: Gustavo Reyes-Teran, M.D. (Instituto Nacional de Enfermedades Respiratorias) · Sites: México, State of Mexico · Age: 1880 yrs
Other3 trials
Introduction of Polymerase Chain Reaction (PCR) in Microbiology and Parasitology
Actively Recruiting
· Sites: Pavia, Lombardy
Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii
Active
· Sites: Brest
Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Actively Recruiting
PI: Santiago Avila, PhD (Center for Research in Infectious Diseases (CIENI)) · Sites: Mexico City, Tlalpan · Age: 1860 yrs

Specialists

Showing 25 of 44View all specialists →
EM
Emily G McDonald, MD MSc
Specialist
PI on 3 active trials
LP
Laura Cox, PhD
Specialist
PI on 1 active trial
CM
Christine Robin, MD
WORCESTER, MA
Specialist
PI on 1 active trial
CM
Christine E. Kistler, MD, MASc
PITTSBURGH, PA
Specialist
PI on 1 active trial
LM
Laura C. Hanson, MD, MPH
Specialist
PI on 1 active trial
AM
Alison Morris-Gimbel, MD
Specialist
PI on 2 active trials1 Pneumocystosis publication
AB
Adrien BARRAUD
Specialist
PI on 1 active trial
LD
Lingli Dong
Specialist
PI on 2 active trials80 Pneumocystosis publications
TF
Todd C Lee, MD MPH FIDSA
Specialist
PI on 3 active trials
VP
Vanessa Merker, PhD
Boston, Massachusetts
Specialist

Rare Disease Specialist

PI on 3 active trials
SP
Scott Plotkin, MD, PhD
BUFFALO, NY
Specialist
PI on 3 active trials
JM
Joseph A Kovacs, M.D.
Specialist
PI on 6 active trials
AM
ANDRES F HENAO, MD
LAWRENCEVILLE, GA
Specialist
PI on 1 active trial1 Pneumocystosis publication
AP
Albert SOTTO, Md, PhD
Specialist
PI on 3 active trials
LM
Laurence Lachaud, MD
Specialist
PI on 1 active trial1 Pneumocystosis publication
JM
John M Harris, Jr., MD
Specialist
PI on 1 active trial
MM
Madhukar H Trivedi, MD
DALLAS, TX
Specialist
PI on 1 active trial
AB
Antoine Berry
Specialist
PI on 1 active trial
HW
Hughes WT
Specialist
PI on 1 active trial
BM
B Montgomery
Specialist
PI on 1 active trial
SM
Shabir Madhi
Specialist
PI on 1 active trial
FZ
Fengchun Zhang
Specialist
PI on 4 active trials
DM
Dohn M
Specialist
PI on 1 active trial
CC
Cunwei Cao
Specialist
PI on 1 active trial
SA
Santiago Avila
SAN FRANCISCO, CA
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Pneumocystosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open PneumocystosisForum →

No community posts yet. Be the first to share your experience with Pneumocystosis.

Start the conversation →

Latest news about Pneumocystosis

Disease timeline:

New recruiting trial: Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

A new clinical trial is recruiting patients for Pneumocystosis

New recruiting trial: Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification

A new clinical trial is recruiting patients for Pneumocystosis

New recruiting trial: Introduction of Polymerase Chain Reaction (PCR) in Microbiology and Parasitology

A new clinical trial is recruiting patients for Pneumocystosis

New recruiting trial: Caspofungin for Pneumocystis Pneumonia in PLWHIV.

A new clinical trial is recruiting patients for Pneumocystosis

New recruiting trial: Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

A new clinical trial is recruiting patients for Pneumocystosis

New recruiting trial: Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

A new clinical trial is recruiting patients for Pneumocystosis

New recruiting trial: Implementation of the Personalized Care Plan (PCP) Proposed at the End of Step 2 of the ICOPE Program

A new clinical trial is recruiting patients for Pneumocystosis

New recruiting trial: Sulfamethoxazole Prophylaxis Duration After Renal Transplantation

A new clinical trial is recruiting patients for Pneumocystosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the best treatment option for me given my other health conditions and medications?,How long will I need to take antibiotics, and what side effects should I watch for?,Should I be on preventive antibiotics after I recover, and for how long?,What is causing my immune system to be weakened, and how can we address that?,How will we know if the treatment is working, and when should I expect to feel better?,Am I at risk of getting this infection again, and what can I do to prevent it?,Are there any activities or exposures I should avoid while I recover or afterward?

Common questions about Pneumocystosis

What is Pneumocystosis?

Pneumocystosis, also called Pneumocystis pneumonia (PCP), is a serious lung infection caused by a fungus called Pneumocystis jirovecii (previously known as Pneumocystis carinii). This fungus is found almost everywhere in the environment and does not usually cause illness in healthy people. However, in people whose immune system is weakened — such as those living with HIV/AIDS, people receiving chemotherapy, or organ transplant recipients on immune-suppressing medications — the fungus can multiply in the lungs and cause a dangerous infection. The infection mainly affects the lungs, causing inf

How is Pneumocystosis inherited?

Pneumocystosis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Pneumocystosis?

Yes — 7 recruiting clinical trials are currently listed for Pneumocystosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Pneumocystosis?

25 specialists and care centers treating Pneumocystosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.